Aimery de Gramont

Aimery de Gramont developed the de Gramont (FOLFOX) regimen and led the MOSAIC trial establishing FOLFOX as the gold standard adjuvant therapy for stage III colon cancer, resulting in global regulatory approval. His contributions to fluoropyrimidine and oxaliplatin combination regimens have shaped first-line colorectal cancer treatment for decades. He pioneered the use of leucovorin-modulated 5-fluorouracil infusion regimens that became foundational in CRC management. De Gramont's legacy in adjuvant colon cancer therapy represents one of the most impactful contributions in gastrointestinal oncology.